colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate
COLY-MYCIN S (colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate) by Pfizer is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1962.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
Coly-Mycin S is a fixed-combination otic suspension containing two bactericidal antibiotics (colistin and neomycin), a corticosteroid (hydrocortisone acetate), and a surfactant (thonzonium bromide). It treats superficial bacterial infections of the external auditory canal caused by susceptible gram-positive and gram-negative organisms. The formulation works through dual antibiotic mechanisms (cell membrane disruption and protein synthesis inhibition) combined with anti-inflammatory action.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking team investment and transition toward generic management or portfolio de-emphasis.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on COLY-MYCIN S at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Roles linked to Coly-Mycin S are primarily defensive and compliance-focused rather than growth-oriented. This is a stable but non-strategic assignment within Pfizer's portfolio, offering limited visibility, promotional budget, or career acceleration potential.